Citius Pharmaceuticals to Hold Investor Call on Recent and Upcoming Developments

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") has announced an upcoming investor call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET. This conference will cover both recent and forthcoming developments within the company. The call will feature Leonard Mazur, Citius Chairman and CEO, along with various management team members. After the management's initial discussion, there will be a question and answer session.

Citius Pharma is a biopharmaceutical company focused on the development and commercialization of unique critical care products. One of its major achievements came in August 2024, when the FDA approved LYMPHIR, a targeted immunotherapy designed for the treatment of cutaneous T-cell lymphoma.

In addition to LYMPHIR, Citius Pharmaceuticals has a robust late-stage pipeline. This includes Mino-Lok®, an antibiotic lock solution aimed at salvaging catheters in patients suffering from catheter-associated bloodstream infections. The company has also developed CITI-002 (Halo-Lido), a topical formulation intended for hemorrhoid relief. The development of Mino-Lok and Halo-Lido has seen substantial progress, with pivotal trials completed in 2023. The Phase 3 trial for Mino-Lok successfully met both its primary and secondary endpoints. Similarly, the Phase 2b trial for Halo-Lido was also concluded last year.

Currently, Citius is in active discussions with the FDA to determine the subsequent steps required for advancing both Mino-Lok and Halo-Lido. The company’s dedication to creating first-in-class therapies for critical care situations positions it as a noteworthy entity in the biopharmaceutical field.